Adrenal Hyperplasia Among Young People With PCOS
Adrenal Hyperplasia Among Young People With PCOS
Background:

 - Polycystic ovarian syndrome (PCOS) is a group of disorders related to problems with the
 secretion of certain hormones, which can lead to reproductive and other issues in women.
 Frequent complications of PCOS include irregular menstruation, development of ovarian cysts,
 and insulin resistance. The adrenal glands, which sit on top of the kidney, are involved in
 the production of certain hormones and the regulation of steroid levels in the blood, and may
 be affected in women with PCOS. Researchers are interested in studying possible connections
 between the adrenal glands and PCOS in young women who have been diagnosed with PCOS and
 healthy volunteers with normal menstrual function.

 Objectives:

 - To investigate possible connections between adrenal gland steroid hormone secretion and
 polycystic ovarian syndrome.

 Eligibility:

 -  Women between 16 and 29 years of age who have been diagnosed with PCOS, or who are
 healthy volunteers with normal menstrual function.

 -  Participants must be willing to discontinue the use of oral contraceptives or any other
 medications that alter steroid hormone production for at least 1 month before the start
 of the study.

 Design:

 -  Participants will be screened with a physical examination, medical history, and blood
 and urine tests. All participants will also have a pelvic (ovarian) ultrasound.

 -  All participants will be admitted to the hospital for a 1-week testing period, which
 will involve the following tests:

 -  Regular blood draws for two 2-hour periods (late evening and early morning) to measure
 hormone levels

 -  Fasting blood draws with a dose of corticotropin to test the body's adrenal function

 -  Hormone level measurement following regular doses of dexamethasone (a drug that controls
 the function of the adrenal gland)

 -  Daily urine collection for 6 days.

 -  Other studies, such as imaging studies of the adrenal glands, may be conducted as
 required by the study researchers.
Polycystic ovarian syndrome (PCOS) is a heterogeneous group of disorders presenting with
 hyperandrogenism in adolescents and young women. The etiology of this condition remains
 unknown, despite its many identified links to insulin resistance, hypertension and metabolic
 syndrome, as well as its potential connection to the various forms of congenital adrenal
 hyperplasia (CAH).

 The adrenal glands are the only source in the body of adrenocortical steroids. In normal
 physiology, the pituitary hormone ACTH regulates the secretion of glucocorticoids, while the
 secretion of mineralocorticoids is controlled by the renin-angiotensin system. In addition to
 these two steroids, the adrenal gland secretes lesser amounts of intermediate metabolites of
 these steroids, as well as the sex-steroids DHEA, DHEAS, androstenedione, testosterone,
 estrogen, and estrone. Dysregulated secretion of any of these hormones can be caused by the
 development of hyperplasia of the adrenocortical tissue, which may be mild and lead to
 specific clinical syndromes depending on the identity of the secreted hormones. Bilateral
 adrenocortical hyperplasia (BAH) is now an increasingly diagnosed cause of adrenal
 dysfunction.

 We propose that there is a subgroup of patients with PCOS who actually have non-CAH primary
 forms of BAH. To investigate this possibility, we propose to study the
 hypothalamic-pituitary-adrenal axis (HPAA) over the next 2 years in 120 young girls and women
 (ages 16 to 25 years) that we will compare to 30 age- and race-matched normal females.
 Patients will be recruited primarily (although not exclusively) from a busy New York City
 clinic run by the Pediatric Endocrine Division at the Infants and Children's Hospital of
 Brooklyn at Maimonides and SUNY Downstate. All patients will undergo standard testing of the
 HPAA including oral low- and high-dose dexamethasone (DEX)-suppression testing (Liddle s
 test). Paradoxical rise of cortisol and/or other steroid metabolites in response to DEX is
 considered a sensitive test for the diagnosis of BAH. Patients with such responses will be
 molecularly investigated for the known causes of BAH (GNAS, PRKAR1A, PDE11A, PDE8B and other
 mutations).

 The first goal of this study is to identify any possible contributions of the BAH phenotypes
 and genotypes to the pathophysiology of PCOS, a yet unknown factor in the etiology of this
 multifaceted disorder. The second goal is to perform a comparative analysis of the expression
 of large sets of genes in cells of these patients using gene arrays and other genetic
 analyses. This study will generate important information about the molecular pathways that
 are affected in this subgroup of patients with PCOS. Thirdly, this study will also allow for
 the collection of DNA from affected and non-affected relatives of the patients to perform
 genetic studies and identify causative genetic defects. Finally, the study is expected to
 lead to new diagnostic and therapeutic methods for at least certain forms of PCOS.
-  INCLUSION CRITERIA FOR PATIENTS:

 Women 16-24 years old with PCOS defined as biochemical hyperandrogenism with associated
 findings of either menstrual irregularity and /or polycystic ovaries on ultrasound;
 hyperandrogenism defined as elevation of any of the following androgens: free testosterone,
 total testosterone, DHEAS, DHEA, 17 0H progesterone, androstenedione, 17OH pregnenolone; a
 polycystic ovary on ultrasound should either have 12 follicles measuring 2-9 mm in
 diameter, or have an increased ovarian volume of 10 CC or greater; menstrual irregularity
 defined as: Amenorrhea refers to absence of bleeding for at least three usual cycle
 lengths; oligomenorrhea refers to bleeding that occurs at an interval greater than 35 days.

 We would like patients to have oligomenorrhea for at least six usual cycle lengths.
 Patients have to be off oral contraceptive pills or any other medications that alter
 steroidogenesis for at least one month prior to participating in the study

 INCLUSION CRITERIA FOR CONTROLS:

 Women 18-25 years old with normal menstrual function; they have to be off oral
 contraceptive pills or any other medications that alter steroidogenesis for at least one
 month prior to participating in the study.

 EXCLUSION CRITERIA FOR PATIENTS:

 Patients who have hyperandrogenism due to 21 hydroxylase deficiency non- classic adrenal
 hyperplasia androgen secreting neoplasms

 Women with known or suspected androgenic/anabolic drug use

 Women with severe insulin resistance-acanthosis nigricans syndrome; Fasting insulin levels
 are obtained to rule out syndromes of severe insulin resistance and hyperandrogenism; if
 insulin is above 80 mU/mL in the fasting state, and/or >300 mU/mL following a 2- or 3-hour
 oral glucose tolerance test (obtained elsewhere), patients are not eligible.

 Women with thyroid dysfunction, hyperprolactinemia, (defined as prolactin level greater
 than or equal to 3 times the upper reference limit), less than 2 years post menarche, and
 patients on medications that alter steroidogenesis such as oral contraceptive pills, for
 less than a month prior to the date of inclusion in the study. (see above: patients have to
 be off oral contraceptive pills or any other medications that alter steroidogenesis for at
 least one month prior to participating in the study)

 Women with prior history of pregnancy.

 EXCLUSION CRITERIA FOR CONTROLS:

 Young women with hyperandrogenemia, hirsutism or known adrenal tumors or other endocrine
 diseases, patients on multiple medications, known insulin resistance, or any other chronic
 or acute illness are not eligible as controls for this study.